Insights into Healthcare M&A: Q3 2024 Trends Healthcare M&A activity increased in the third quarter of 2024, with 33 transactions vs. 21 in 2023. Healthcare Services was the most active healthcare subsector, representing 42% of deal volume, with the most notable transaction being TowerBrook’s and CD&R’s $8.3B acquisition of R1 RCM. Biopharma transaction volume increased slightly in the third quarter of 2024, with 10 transactions vs. 9 in 2023, while transaction value declined from $13 billion to $9 billion. Oncology was the most active therapeutic area. We expect Biopharma M&A activity to remain dynamic as large biopharmaceutical companies seek to fill revenue and pipeline gaps via acquisitions of development-stage companies. We continue to expect both private and publicly traded pre-commercial biopharma companies to evaluate the full range of strategic alternatives, including partnerships, mergers and sale transactions. Given an improving macroeconomic backdrop and corresponding capital markets environment, we also expect private development-stage private companies to increasingly evaluate IPOs. LEARN MORE
News Leerink Partners Announces Strategic Hires, Advancing Buildout of World Class Mergers & Acquisitions Team November 2024
News Tom Davidson Joins Leerink Partners as Co-President and Co-Head of Global Investment Banking November 2024
News Leerink Partners Expands Healthcare Medical Technology, Life Science Tools and Diagnostics Team with the Addition of Industry Veterans Dr. Bernhard Sakmann and Justin Reed October 2024
News Leerink Partners’ Affiliate, MEDACorp, Launches the Center for Pharmacoeconomics to Evaluate the Societal Impact of Healthcare Treatments October 2024
